PL1928821T3 - Pochodne karboksyamidowe jako antagoniści receptora muskarynowego - Google Patents

Pochodne karboksyamidowe jako antagoniści receptora muskarynowego

Info

Publication number
PL1928821T3
PL1928821T3 PL06795581T PL06795581T PL1928821T3 PL 1928821 T3 PL1928821 T3 PL 1928821T3 PL 06795581 T PL06795581 T PL 06795581T PL 06795581 T PL06795581 T PL 06795581T PL 1928821 T3 PL1928821 T3 PL 1928821T3
Authority
PL
Poland
Prior art keywords
receptor antagonists
muscarinic receptor
carboxamide derivatives
carboxamide
derivatives
Prior art date
Application number
PL06795581T
Other languages
English (en)
Inventor
Paul Alan Glossop
Simon John Mantell
Ross Sinclair Strang
Christine Anne Louise Watson
Anthony Wood
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of PL1928821T3 publication Critical patent/PL1928821T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL06795581T 2005-09-21 2006-09-01 Pochodne karboksyamidowe jako antagoniści receptora muskarynowego PL1928821T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71947705P 2005-09-21 2005-09-21
US71946705P 2005-09-21 2005-09-21
US71946805P 2005-09-21 2005-09-21
EP06795581A EP1928821B1 (en) 2005-09-21 2006-09-01 Carboxamide derivatives as muscarinic receptor antagonists
PCT/IB2006/002727 WO2007034325A1 (en) 2005-09-21 2006-09-01 Carboxamide derivatives as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
PL1928821T3 true PL1928821T3 (pl) 2009-06-30

Family

ID=37698323

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06795581T PL1928821T3 (pl) 2005-09-21 2006-09-01 Pochodne karboksyamidowe jako antagoniści receptora muskarynowego

Country Status (42)

Country Link
US (3) US7772223B2 (pl)
EP (1) EP1928821B1 (pl)
JP (1) JP4221447B1 (pl)
KR (1) KR100976909B1 (pl)
CN (1) CN101268046B (pl)
AP (1) AP1983A (pl)
AR (1) AR055171A1 (pl)
AT (1) ATE420069T1 (pl)
AU (1) AU2006293618B9 (pl)
BR (1) BRPI0616111B8 (pl)
CA (1) CA2623332C (pl)
CR (2) CR9814A (pl)
CU (1) CU20100115A7 (pl)
CY (1) CY1108880T1 (pl)
DE (1) DE602006004768D1 (pl)
DK (1) DK1928821T3 (pl)
DO (1) DOP2006000202A (pl)
EA (1) EA013083B1 (pl)
EC (1) ECSP088265A (pl)
ES (1) ES2318794T3 (pl)
GE (1) GEP20104880B (pl)
GT (1) GT200600422A (pl)
HN (1) HN2006032615A (pl)
HR (1) HRP20090127T3 (pl)
IL (1) IL189453A (pl)
MA (1) MA29839B1 (pl)
ME (1) ME01106B (pl)
MX (1) MX2008002805A (pl)
MY (1) MY143581A (pl)
NL (1) NL2000241C2 (pl)
NO (1) NO340975B1 (pl)
NZ (1) NZ566023A (pl)
PE (1) PE20070460A1 (pl)
PL (1) PL1928821T3 (pl)
PT (1) PT1928821E (pl)
RS (2) RS51680B (pl)
SI (1) SI1928821T1 (pl)
TN (1) TNSN08137A1 (pl)
TW (1) TWI322143B (pl)
UY (1) UY29798A1 (pl)
WO (1) WO2007034325A1 (pl)
ZA (1) ZA200801432B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
CA2664057A1 (en) * 2006-09-22 2008-03-27 Pfizer Limited Azetidine derivatives as muscarinic receptor antagonists
SI2125714T1 (sl) * 2007-03-16 2011-10-28 Pfizer Ltd Hidrokloridna sol 5-(3-(3-hidroksifenoksi)azetidin-1-il)-5-metil-2,2-difenilheksanamida
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
CN103201244B (zh) * 2010-08-26 2015-06-17 阿尔比马尔公司 用于制备1-溴代-2-(环丙基甲氧基)-5-氟代-4-甲氧基苯的方法
CN103242214B (zh) * 2013-05-02 2016-04-06 陕西步长高新制药有限公司 一种吲哚衍生物及其制备方法
KR101538846B1 (ko) 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법
EP3596046A1 (en) 2017-03-15 2020-01-22 Mylan Laboratories Ltd. Novel polymorphs of (5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide hydrochloride
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
CN113015721B (zh) 2018-09-19 2025-07-25 科迪华农业科技有限责任公司 毒莠定卤素类似物的制备
CN111423434A (zh) * 2019-01-09 2020-07-17 四川海思科制药有限公司 一种碳酰胺衍生物及其制备方法
WO2020261160A1 (en) * 2019-06-25 2020-12-30 Mylan Laboratories Limited Methods and intermediates for preparing hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
CN116033893A (zh) 2020-06-26 2023-04-28 迈兰制药英国有限公司 包含5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的制剂
WO2023049696A1 (en) * 2021-09-21 2023-03-30 Corteva Agriscience Llc Methylation of 2-chloro-6-fluorophenol

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886574A (en) 1956-11-19 1959-05-12 Upjohn Co Quaternary ammonium salts of 2, 2-diphenyl-4, 4-dimethyl-4-pyrrolidino-butyramide
US4219559A (en) 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
GB8824262D0 (en) * 1988-10-17 1988-11-23 Pfizer Ltd Therapeutic agents
US5070087A (en) * 1989-05-08 1991-12-03 A. H. Robins Company, Incorporated Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
CN1104239C (zh) * 1996-12-02 2003-04-02 杏林制药株式会社 新颖的n－取代的吡咯烷衍生物及其制备方法
EP0848964B1 (de) * 1996-12-17 2007-07-25 Filtertek B.V. Rückschlagventil, insbesondere für die Medizintechnik
JPH11100366A (ja) * 1997-09-29 1999-04-13 Kyorin Pharmaceut Co Ltd 新規ｎ−置換環状アミン誘導体及びその製造法
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
CA2470956C (en) 2001-12-20 2011-08-02 Laboratorios S.A.L.V.A.T., S.A. 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives and their use as muscarinic receptor antagonists
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
EP1375508A1 (en) 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
KR20050043967A (ko) 2002-09-17 2005-05-11 액테리온 파마슈티칼 리미티드 1-피리딘-4-일-요소 유도체

Also Published As

Publication number Publication date
AP1983A (en) 2009-03-24
HN2006032615A (es) 2010-10-04
US20100029720A1 (en) 2010-02-04
US8486992B2 (en) 2013-07-16
SI1928821T1 (sl) 2009-04-30
DE602006004768D1 (de) 2009-02-26
CA2623332C (en) 2012-05-01
CN101268046B (zh) 2012-07-25
AU2006293618B9 (en) 2009-10-29
NL2000241A1 (nl) 2007-03-22
CY1108880T1 (el) 2014-07-02
TW200745024A (en) 2007-12-16
ECSP088265A (es) 2008-04-28
GT200600422A (es) 2007-05-28
KR100976909B1 (ko) 2010-08-18
JP4221447B1 (ja) 2009-02-12
NO340975B1 (no) 2017-07-31
UY29798A1 (es) 2007-04-30
MY143581A (en) 2011-05-31
IL189453A (en) 2014-06-30
DK1928821T3 (da) 2009-03-16
TWI322143B (en) 2010-03-21
BRPI0616111B1 (pt) 2019-10-08
WO2007034325A1 (en) 2007-03-29
PT1928821E (pt) 2009-03-10
CA2623332A1 (en) 2007-03-29
EA200800540A1 (ru) 2008-08-29
JP2009508933A (ja) 2009-03-05
RS51680B (sr) 2011-10-31
ATE420069T1 (de) 2009-01-15
TNSN08137A1 (fr) 2009-07-14
BRPI0616111B8 (pt) 2021-05-25
US20110251164A1 (en) 2011-10-13
US7772223B2 (en) 2010-08-10
US20070105831A1 (en) 2007-05-10
NL2000241C2 (nl) 2009-01-05
AR055171A1 (es) 2007-08-08
MX2008002805A (es) 2008-04-07
AU2006293618B2 (en) 2009-10-08
RS50855B (sr) 2010-08-31
EP1928821B1 (en) 2009-01-07
ES2318794T3 (es) 2009-05-01
KR20080037103A (ko) 2008-04-29
HK1117163A1 (en) 2009-01-09
ZA200801432B (en) 2009-07-29
CU20100115A7 (es) 2011-10-14
MA29839B1 (fr) 2008-10-03
AU2006293618A1 (en) 2007-03-29
US8268881B2 (en) 2012-09-18
NZ566023A (en) 2010-02-26
CR9814A (es) 2008-04-16
CR20130209A (es) 2013-09-19
NO20081001L (no) 2008-03-25
ME01106B (me) 2013-03-20
EA013083B1 (ru) 2010-02-26
CU23910B1 (pl) 2013-06-29
IL189453A0 (en) 2008-08-07
EP1928821A1 (en) 2008-06-11
BRPI0616111A2 (pt) 2011-06-07
RS20080119A (sr) 2009-05-06
GEP20104880B (en) 2010-01-11
CN101268046A (zh) 2008-09-17
HRP20090127T3 (en) 2009-06-30
DOP2006000202A (es) 2007-04-15
PE20070460A1 (es) 2007-05-14

Similar Documents

Publication Publication Date Title
IL189453A0 (en) Carboxamide derivatives as muscarinic receptor antagonists
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
ZA200708028B (en) Acetylenyl-pyrazolo-pyrimidine derivatives as mGluR2 antagonists
SI2094690T1 (sl) Derivati 2-aza-biciklo(3.1.0)heksana kot antagonisti receptorja za oreksin
IL187424A0 (en) C5a RECEPTOR ANTAGONISTS
IL199015A0 (en) Quinuclidinol derivatives as muscarinic receptor antagonists
ZA200709147B (en) Pyrimidindione derivatives as prokineticin 2 receptor antagonists
ZA200705237B (en) C5A receptor antagonists
IL190686A0 (en) Il-21 receptor antagonists
IL192308A0 (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
AP2008004441A0 (en) Piperdin-4-ylpyrazin-2-ylamine derivatives as fastdissociating dopamine 2 receptor antagonists
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
ZA200903499B (en) Indoles which act as via receptor antagonists
IL178622A0 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
ZA200802339B (en) Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
ZA200903496B (en) Spiro-piperidine derivatives as via receptor antagonists
PL1912976T3 (pl) Pochodne indol-3-ilokarbonylopiperydynobenzoimidazolu jako antagoniści receptora V1a
HU0501169D0 (en) New phenantridine derivatives as selective bradykinin b1 receptor antagonists
IL185640A0 (en) Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists
AP2008004537A0 (en) Muscarinic receptor antagonists
ZA200806223B (en) Muscarinic receptor antagonists
GB0525029D0 (en) Receptor Antagonist
ZA200508200B (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
HK1124601A (en) Muscarinic receptor antagonists
ZA200608369B (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists